CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
DURHAM, N.C., Feb. 28, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix, will present a corporate overview at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
